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A number of th ienopyrimidines derivatives have shown potent YEGFR2 (Vasculnr Endothelium Growth Factor 
Receptor2) inhibition activity [ 1]. YEGF is a surrogate marker of angiogenesis that activates VEGFR2 in 
endothelial cells. VEGF induces proliferation, migration and anastomosis of these cells. Here we present the 
synthesis of new l-aryl-3-[4-(thieno[3,2-d]pyrimidin-4-yloxy)phenyl]ureas, by reaction of 4-aminophenol with 
4-chlorothieno[3,2-d]pyrimidine giving compound 1, which was reacted with arylisocyanates to give the 
corresponding I ,3-diarylureas Za-c (Scheme). 
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These were evaluated for inhibition of YEGFR2 tyrosine kinase act ivity using enzymatic assays and showed 
good inhibition abi lity . The rational for the inhibition is also discussed using docking. To examine the activity of 
these compounds in endothelial cells, Human Umbilical Vein Endothelial Cells (HUYECs) were cultured in 
M 199, supplemented with 20% FBS containing 60 ng/mL of YEGF, in the presence or absence of each 
compound and in the concentrat ions 0. 1 ~M. 1.0 ~M and I 0 ~M or control (0.1% DMSO). Cell viabil ity was 
n1easured by MTS assay at 24h, revealing a decrease in the percentage of viable cells upon incubation with 
higher concentrat ions. This was accompanied by a reduction above 0.5 ~tM in the proliferation of HUYECs 
evaluated by the incorporation of BrdU quantified by ELISA assay. These fi ndings suggest that these 
compounds are able to inhibit proli feration. G iven the established role of YEGFR2 in proliferation and migration 
of endothelial cells, these molecules are promising anti-angiogenic agents that can be used for therapeutic 
purposes in pathological conditions where angiogenesis is exacerbated, such as in cancer. 
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